An important goal of human genomic research is the identification and characterization of genetic contributors to neurodevelopmental disease. Recurrent deletions and duplications of specific segments of our genome have emerged as some of the most common mutations identified in patients showing abnormal neurodevelopment. Collectively, these genomic losses and gains explain ~5-10% of autism spectrum disorder, schizophrenia, and intellectual disability. Despite intense interest in these rearrangements and their associated diseases, reciprocal genomic disorders (RGDs), relatively few studies have addressed their functional consequences at the molecular level. This project will leverage genome editing technology to generate a series of cell lines with deletions or duplications of interest against an isogenic background. RNA sequencing will then serve as a platform to investigate global changes in gene expression resulting from each rearrangement over the course of in vitro neuronal differentiation. First, I will establish, differentiate, and characterize cellular models for ten RGDs to describe and compare the transcriptional consequences of deletion and duplication at ten genomic intervals (Aim 1). Second, I will develop a method for parallel genome engineering and apply it to obtain cell lines with altered dosage of smaller segments and single genes within four RGD regions (Aim 2). Third, I will differentiate and characterize cell lines with these smaller rearrangements to identify genetic drivers underlying dysregulation observed in the four corresponding RGDs (Aim 3). This research will provide a detailed assessment and comparison of transcriptional effects of the most common RGD rearrangements. The parallel genome editing strategy will be made freely available to the scientific community, allowing researchers to generate hundreds or thousands of isogenic cell lines differing only by specified mutations of interest. Finally, genetic driver analyses promise to implicate new genes in the etiology of neurodevelopmental disease. Overall, by enhancing our molecular understanding of RGDs, this study will inform efforts to develop effective targeted treatments.

Public Health Relevance

This project will yield insight into how deletions and duplications of particular regions of our genome often translate into neurodevelopmental disease. The work will define molecular consequences of these genomic rearrangements and enable the discovery of specific genes and biological pathways involved in pathogenesis. The results will enhance our understanding of several of the most common mutations observed in autism, schizophrenia, and intellectual disability and promise to ultimately facilitate therapeutic development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32MH115614-01
Application #
9470125
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Van'T Veer, Ashlee V
Project Start
2017-09-19
Project End
2019-09-18
Budget Start
2017-09-19
Budget End
2018-09-18
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114